Iritis

Researchers are investigating the effects of an investigational cold treatment device called ETX-4143 on the eye's surface anatomy and inflammatory response in people with chronic ocular surface pain (COSP). This study aims to understand changes to corneal surface nerves and inflammatory mediators after treatment, while also evaluating the safety of this cooling device. The study involves detailed imaging and tear sample analysis to learn more about the condition and treatment impact. The ETX-4143 Device is a handheld cooling tool containing a frozen mixture that cools metallic probes touching the eye's conjunctival surface without direct contact with the frozen mixture. Before treatment, local anesthesia and a corneal shield are applied to protect the eye. Participants will receive a 4-minute cold treatment to the worse eye using this device. This single-center study will treat 5 adults with chronic ocular surface pain and follow them for 12 weeks. Participants will be screened for chronic ocular surface pain and will complete weekly eye pain questionnaires for 12 weeks. Clinic visits at 2, 6, and 12 weeks after treatment will include corneal surface imaging and tear sample collection. Both eyes will be assessed with confocal microscopy and tear osmolarity tests, using the untreated eye as a control. The main measurement is corneal nerve imaging analysis over the 12-week period, alongside safety monitoring by the medical team.

This research aims to collect information about clinical features and treatment histories in children under 18 years who have uveitis. It seeks to understand how often different types of uveitis occur in children and the clinical and demographic characteristics of each subtype. The study focuses on both new and established cases of uveitis in pediatric patients. Participants are grouped into those with recent uveitis onset (within 6 months) and those with established uveitis (onset more than 6 months ago). Children with recent onset will have their medical charts reviewed over 12 months, while all participants complete a single enrollment visit with their doctor. The study does not involve any investigational treatments but observes children with active or inactive uveitis regardless of current or past treatment. During the enrollment visit, clinical data will be collected to measure the frequency of uveitis subtypes in children under 18. For recent onset cases, ongoing chart reviews over a year will provide additional information on disease progress and management. Participants' medical history, treatment status, and disease characteristics will be documented, contributing to a better understanding of pediatric uveitis. The study lasts for the enrollment period and an additional 12 months of observation for some children.

Researchers are evaluating the effectiveness of YUTIQ4 0.18 mg intravitreal implant for managing chronic non-infectious uveitis. This observational study divides participants into two groups: one receiving the YUTIQ implant and the other receiving traditional therapy with glucocorticoids alone or combined with immunosuppressants. The study aims to assess anti-inflammatory effects and relapse reduction over time. Participants in the YUTIQ group receive a 0.18 mg implant injected into the designated study eye and are followed for up to 36 months. The traditional therapy group receives glucocorticoids or glucocorticoids plus immunosuppressants and is also monitored for up to 36 months. The study compares outcomes between these two groups throughout the follow-up period. Participants will undergo assessments including best corrected visual acuity (BCVA), anterior chamber and vitreous inflammation, optical coherence tomography (OCT), and corticosteroid dose changes. Researchers will track these outcomes at regular visits over 12 to 36 months to evaluate changes in vision, inflammation, and recurrence rates. Safety and side effects will also be monitored during the study period.

Phacoemulsification is a common cataract surgery performed under topical anesthesia, which is generally safe but can cause pain, anxiety, and discomfort for some patients. This research evaluates the effect of oral anti-anxiety medication, specifically Alprazolam, on improving patient satisfaction during second eye cataract surgery. The study aims to clarify whether oral sedation can reduce pain, anxiety, and side effects like nausea and dizziness compared to no sedation during phacoemulsification. Patients will receive either a single oral dose of Alprazolam or a placebo tablet 30 minutes before surgery. The dose of Alprazolam is 0.5 mg for most patients, with a reduced 0.25 mg dose for those over 65 years or with liver disease. The study compares these groups to assess how oral sedation affects anxiety, pain, and surgical satisfaction. This is an extension study involving patients undergoing surgery on their second eye with topical anesthesia. During the trial, participants will complete questionnaires assessing pain, anxiety, and overall satisfaction before and after surgery. Researchers will monitor intraoperative discomfort and postoperative anxiety levels. Data from approximately 250 patients will be collected and analyzed for these outcomes. This study runs from March 2025 to December 2027, focusing on improving cataract surgery experiences safely and conveniently.

This research aims to explore the use of optical coherence tomography (OCT) scans to analyze inflammation in the front part of the eye, specifically in people with uveitis. The study is observational, meaning it observes and collects data without testing a new treatment. It investigates whether OCT can effectively image and grade the level of inflammation in eyes with both active and inactive uveitis. Participants will have OCT scans taken of the anterior chamber of their eyes to capture detailed images of inflammation. The study does not involve any treatment or intervention but focuses on gathering imaging data. This approach helps determine if OCT can be a reliable tool for assessing eye inflammation. During the study, participants will undergo the OCT imaging process, and researchers will evaluate these images to measure the degree of inflammation. The main outcome is to objectively assess inflammation levels over one year. Participants may also be asked about their ability to provide informed consent. The study is conducted over several years, allowing careful observation of inflammation patterns in uveitis.

Researchers are developing and managing the AnovaOS Network Powered Patient Registry to collect real-world patient data across various diseases globally. This registry aims to capture meaningful clinical information on diagnosis, infection course, treatments, and outcomes to enhance understanding and support future clinical trials and observational studies. The registry serves as a resource to better understand, prevent, diagnose, and treat diverse health conditions. Participants' data will be gathered through this registry, which can also be used to recruit individuals for clinical trials and observational studies on promising therapies. The registry collects ongoing information on patients' health status and treatments, enabling long-term monitoring and analysis. This observational study does not involve administering treatments but focuses on data collection and management. Participants will provide information through questionnaires or instruments, either personally or via an informed proxy, with an expected follow-up once per year. The research team will assess natural history, clinical effectiveness, safety, and quality of care over a period of five years. The registry includes patients with a wide range of conditions, and participation requires informed consent and the ability to complete follow-up data collection.

Researchers are investigating autoinflammatory diseases (AID), which involve recurring inflammatory episodes without infection, cancer, or adaptive immune system problems. This study focuses on both monogenic hereditary periodic syndromes and polygenic or multifactorial AID, including rare conditions like Behçet's disease, Still disease, Schnitzler's disease, PFAPA syndrome, chronic recurrent multifocal osteomyelitis, non-infectious uveitis and scleritis, among others. The goal is to gather detailed data to improve understanding and management of these rare diseases through an international collaboration. The study uses the AIDA registry, a secure online platform for collecting demographic, genetic, clinical, laboratory, radiologic, and therapeutic information. Data are gathered retrospectively and prospectively during routine clinical visits scheduled every 3-6 months. Eleven registries focus on different AID conditions, enabling comprehensive data collection to identify clinical patterns, treatment impacts, and long-term outcomes over a period of at least 10 years. Participants provide information during their usual care visits, allowing researchers to track changes in disease activity, organ involvement, inflammatory markers, visual function, pain levels, fatigue, fertility, and socioeconomic factors. The study monitors these outcomes over multiple timepoints up to 120 months. Data privacy is ensured by pseudonymizing patient information. This registry supports multiple clinical studies and aims to enhance knowledge, awareness, and future research on autoinflammatory diseases worldwide.

Researchers are studying birdshot chorioretinopathy (BCR), a rare inflammatory eye disease affecting both eyes, involving the retina and choroid. This disease is linked strongly to the HLA-A29 gene, but the causes and mechanisms are not fully understood. The study aims to analyze the clinical features and variations of BCR in patients, using various imaging methods and standardized tests to assess visual function and quality of life. It also plans to explore genetic factors beyond HLA-A29 by conducting a genome-wide association study to identify other genes related to BCR. This observational study follows patients diagnosed with birdshot chorioretinopathy who test positive for HLA-A29. Physicians will manage treatment independently based on inflammation severity and its impact on vision, while the study collects data without interfering with care. The study uses imaging techniques like fluorescein angiography and indocyanine green angiography to evaluate disease activity and lesion characteristics over time. Participants will undergo standardized visual assessments including visual acuity, visual field, and color vision testing, along with quality of life questionnaires (VFQ-25). Researchers will monitor birdshot lesion size, number, location, pigmentation, edema, and retinal vasculitis during the study, which averages one year of follow-up. This comprehensive monitoring helps understand disease progression and its effects on vision and daily life.

Researchers are studying the relationship between clinical factors and the occurrence of adverse drug reactions in hospitalized patients who receive tropicamide/phenylephrine 8 mg/50 mg/mL. This study aims to identify which clinical determinants may increase the risk of these reactions and provide safety information for this commonly used ophthalmic drug combination. It also seeks to establish safety measures for patients undergoing eye examinations or surgery where these drugs are used. The study involves hospitalized patients scheduled for surgery who will receive two drops of tropicamide/phenylephrine 8 mg/50 mg/mL. Vital signs will be measured before administration and then at several time points afterward, including 5, 15, 30 minutes, and 1, 2, and 3 hours post-administration. Data will be collected using questionnaires and analyzed to find associations between clinical factors and adverse reactions. Participants will be monitored closely through vital sign checks and questionnaires during the study period. Researchers will evaluate adverse drug reactions and clinical determinants to understand their connection. The main outcome is to assess vital signs at set intervals following drug administration and identify any adverse reactions. The study is observational and aims to enhance the safety profile of this medication in hospitalized patients.

This research aims to develop and test a practical model for remote eye care consultation using vision self-testing. It focuses on overcoming barriers faced by patients, clinicians, and the healthcare system when adopting remote consultations, especially issues related to technology trust and visual acuity assessments. The study is observational and involves collaboration between patients, the public, and NHS staff to create a sustainable and inclusive solution. The study uses an innovative approach with the DigiVis app for vision self-testing during remote consultations. It takes place in three diverse NHS eye departments and involves co-designing the implementation model with stakeholders. Patients are assigned to the remote consultation pathway by their clinicians. The model will be evaluated before, during, and after 14 months of operation, including questionnaires completed online by both patients and staff to assess their experiences and attitudes. Participants will complete online questionnaires before and after their remote consultation to measure their views on the e-health technology, while staff will complete surveys to assess how well the technology is integrated into routine practice. The main outcomes include changes in patient perceptions and staff normalization of the technology over 30 months. The study will also collect qualitative data from interviews and focus groups to understand challenges and support model improvements. The overall participation duration can last up to 30 months including follow-up assessments.